Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • Areas of Research

    Dana-Farber has approximately 500 faculty members, with more than 200 principal investigators. Included below is a sampling of some of our areas of research with available licensing opportunities.

    Small Molecule Drugs and Technologies

    Antibody and protein drugs, targets and technologies

    • Multiple myeloma targets; small molecule immunomodulators (PI: Kenneth Anderson, MD)
    • CD-8 Treg/Qa-1 peptide interactions in tumor and auto-immunity; MINK kinase involved in self-tolerance (PI: Harvey Cantor, MD)
    • Tetramer-based identification of new antigens and antibodies from vaccinated cancer patients (PIs: Frank Hodi, MD/Kai Wucherpfennig, MD, PhD)
    • Genetic changes in lung cancers and pre-cancerous lung lesions and identification of molecular therapeutic targets in malignant pleural mesothelioma (PI: Pasi Jänne, MD, PhD)
    • Developing approaches that block MUC1-C subunit function with soluble receptors and antibodies against the MUC1-C extracellular domain (PI: Donald Kufe, MD)
    • USP2a, androgen responsive and over expressed in prostate tumors, and regulates the stability of fatty acid synthase (FAS), essential for tumor cell survival (PI: Max Loda, MD)
    • Human antibody engineering platform; several candidate antibodies (PI: Wayne Marasco, MD, PhD)
    • Proteomics-based methods for in-depth analysis of key molecular events in tumorigenesis (PI: Jarrod Marto, PhD)
    • Lung cancer gene alterations. Sequencing protein kinase, identification of BRAF mutations in lung adenocarcinoma and EGFR mutations in lung adenocarcinoma (PI: Matt Meyerson, MD, PhD)
    • Non-coding RNA, Programmable DNA methylation, and engineering T cells for immunotherapy (PI: Carl Novina, MD, PhD)
    • Tumor microenvironment in breast tumorigenesis, autocrine/paracrine interactions and breast stem cell characterization (PI: Ellis L. Reinherz, MD)
    • Lymphocyte recognition of antigen and the process of T cell activation and differentiation. Structure-function relationship of the T cell receptor (TCR) for antigen in MHC products (CD3-Ti), CD2 and CD4 (PI: Kornelia Polyak, MD, PhD)
    • Characterization of immune reconstitution following allogeneic hematopoietic stem cell transplantation 2 (PI: Jerome Ritz, MD)
    • Translational research on cyclin-dependent kinase inhibitors (p16ink4a) (PI: Geoffrey Shapiro, MD, PhD)
    • Galectin 1 antibodies for cancer therapy; animal models of lymphoma (PI: Margaret Shipp, MD)
    • Oncogene alterations directly from tumor specimens. CRLF2 cytokine receptor, an essential oncogene in 5-10% of adult and pediatric acute lymphoblastic leukemia (PI: David Weinstock, MD)